Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2
- PMID: 2015606
Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2
Abstract
Tumor regression induced in cancer patients by i.v. infusion of interleukin-2 (IL-2) is often accompanied by severe side effects. To investigate whether local administration would affect immune response without the side effects, two 5-day cycles of continuous intraarterial [internal iliac artery] infusion of recombinant interleukin-2 (rIL-2) were performed in 12 patients with transitional cell carcinoma (tumor stage 1, node stage 0, metastasis stage 0, and grade 1-2) of the bladder. Four groups of 3 patients were treated at each of 4 escalating doses of rIL-2 (18 x 10(3), 18 x 10(4), 18 x 10(5), and 18 x 10(6) IU/m2/day) throughout the course of the two IL-2 cycles. This treatment was effective in inducing a marked intratumor inflammatory response, consisting mainly of T-lymphocytes and macrophages. A remarkable dose-dependent increase in the levels of soluble CD25 was observed in the urine of all patients, which was associated constantly with an enhanced number of intratumor CD25+ cells. Intratumor macrophages were often immunoreactive for interleukin-1 and/or tumor necrosis factor, suggesting an activated status. Increased levels of soluble CD25 and CD25+ lymphocytes were observed in peripheral blood only at the two highest doses of rIL-2, while increased percentages of circulating HLA-DR+ and CD71+ lymphoid cells and enhancement of CD3+/CD16+ T-lymphocytes were found at lower doses. Peripheral blood eosinophils were augmented in almost all patients but were rarely increased in situ. We provide evidence that continuous intraarterial infusion of rIL-2 activates host immune response, acting preferentially at the tissue level.
Similar articles
-
Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.Ann Ist Super Sanita. 1990;26(3-4):411-21. Ann Ist Super Sanita. 1990. PMID: 2091503 Review.
-
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.Clin Cancer Res. 2000 Jun;6(6):2268-78. Clin Cancer Res. 2000. PMID: 10873077 Clinical Trial.
-
Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.Cancer Res. 1992 Feb 1;52(3):726-33. Cancer Res. 1992. PMID: 1732060
-
Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.Exp Hematol. 1992 Sep;20(8):962-8. Exp Hematol. 1992. PMID: 1354620
-
Locoregional IL-2 immunotherapy of bladder cancer.Immunopharmacol Immunotoxicol. 1997 Feb;19(1):1-13. doi: 10.3109/08923979709038530. Immunopharmacol Immunotoxicol. 1997. PMID: 9049656 Review. No abstract available.
Cited by
-
Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells.Cell Stress Chaperones. 2013 Nov;18(6):801-8. doi: 10.1007/s12192-013-0422-2. Epub 2013 Apr 12. Cell Stress Chaperones. 2013. PMID: 23580156 Free PMC article.
-
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder.Br J Cancer. 1999 Feb;79(5-6):770-9. doi: 10.1038/sj.bjc.6690124. Br J Cancer. 1999. PMID: 10070868 Free PMC article.
-
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.Drugs. 1993 Sep;46(3):446-514. doi: 10.2165/00003495-199346030-00009. Drugs. 1993. PMID: 7693434 Review.
-
The immunobiological effects of interleukin-2 in vivo.Cancer Immunol Immunother. 1994 Oct;39(4):207-16. doi: 10.1007/BF01525983. Cancer Immunol Immunother. 1994. PMID: 7954522 Free PMC article. Review. No abstract available.
-
Revealing global regulatory perturbations across human cancers.Mol Cell. 2009 Dec 11;36(5):900-11. doi: 10.1016/j.molcel.2009.11.016. Mol Cell. 2009. PMID: 20005852 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials